secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-125869
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics Q3 2024 revenue down 20% to $25.5M; net income falls to $2.9M from $7.5M
--------------------------------------------------------------------------------

- Revenue $25.5M in Q3 2024 vs $32.0M in Q3 2023, down 20% due to lower anti-fibrosis drug sales.
- Net income $2.9M in Q3 2024 vs $7.5M in Q3 2023; nine-month net income $17.3M vs $15.5M.
- Phase 3 trial for F351 in CHB liver fibrosis completed; topline data expected Q1 2025. US Phase 2 for MASH in 2025.
- Commercial launches of avatrombopag (H1 2025) and nintedanib (2025) in China expected.
- Cash and equivalents $15.9M as of Sept 30, 2024; funding runway over 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/0000950170-24-125869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/gyre-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer